TET2 and B-cell non-Hodgkin lymphoma: The findings of the two authors were consistent, with ORRs of 55.0% and 52.0%, respectively, and it was concluded that TET2 deletion appeared to make tumor cells more sensitive in vivo to azacytidine and B-cell lymphoma/leukemia-2 inhibitors.